← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Panacea Innovation Ltd
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0002010692
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 0
- Purchases · 24M
- 2
- Average purchase
- $428.4K
- Median purchase
- $428.4K
- Gross purchase value
- $856.8K
Companies: Atara Biotherapeutics, Inc.
2 SEC accession(s) · 2 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2025-08-19 | Atara Biotherapeutics, Inc. | ATRA | 10% Owner | $670.5K | Open filing |
| 2025-07-21 | Atara Biotherapeutics, Inc. | ATRA | 10% Owner | $186.4K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 100.0% (2/2) | 100.0% (2/2) | +5.3% | +5.3% | +1.4% |
| 20D | 2Small Sample | 100.0% (2/2) | 0.0% (0/2) | -2.3% | -2.3% | -2.5% |
| 60D | 2Small Sample | 100.0% (2/2) | 100.0% (2/2) | +11.5% | +11.5% | +1.5% |
| 120D | 2Small Sample | 100.0% (2/2) | 50.0% (1/2) | -29.4% | -29.4% | -66.7% |
Research patterns
- First purchase in 12M
- 0/1
- Large purchase ≥ $100k
- 2/2
- Cluster buying · 15D
- 2/2
- Buying the dip
- 2/2
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.